Dr Renaud FeltenRhumatologue à Strasbourg

2024RMD openPubMed

Efficacy of BAFF inhibition and B-cell depletion in non-obese diabetic mice as a spontaneous model for Sjögren's disease

2024Annals of the rheumatic diseasesPubMed

Examining the biological pathways underlying clinical heterogeneity in Sjogren's syndrome: proteomic and network analysis

2023Rheumatology (Oxford, England)PubMed

Identification of new candidate drugs for primary Sjögren's syndrome using a drug repurposing transcriptomic approach

2023Annals of the rheumatic diseasesPubMed

Response to: 'Correspondence on 'Interleukin 6 receptor inhibition in primary Sjögren syndrome: a multicentre double-blind randomised placebo-controlled trial'' by de Wolff et al

2023RMD openPubMed

Alteration of innate lymphoid cell homeostasis mainly concerns salivary glands in primary Sjögren's syndrome

2023Joint bone spinePubMed

Non-primary Sjogren's Syndrome: Secondary or associated?

2023Annals of the rheumatic diseasesPubMed

Response to: 'Correspondence on 'Interleukin 6 receptor inhibition in primary Sjögren syndrome: a multicentre double-blind randomised placebo-controlled trial'' by Wang et al

2022Arthritis & rheumatology (Hoboken, N.J.)PubMed

Variability of Primary Sjögren's Syndrome Is Driven by Interferon-α and Interferon-α Blood Levels Are Associated With the Class II HLA-DQ Locus

2022Joint bone spinePubMed

Polymyalgia rheumatica associated with primary Sjögren's syndrome: A French multicentric retrospective study

2022Acta neuropathologica communicationsPubMed

Inclusion body myositis and Sjögren's syndrome: the association works both ways

2026Joint bone spinePubMed

Preconception, pregnancy and postpartum periods in spondyloarthritis: Unmet needs and challenges from a patients and rheumatologists surveys

2026Therapeutic advances in musculoskeletal diseasePubMed

Spondyloarthritis in the peripartum period: a systematic review of current knowledge and clinical implications

2026Joint bone spinePubMed

Evolving Economic Burden of Spondyloarthritis (2015-2023): A Nationwide Analysis of Direct and Indirect Costs

2026Joint bone spinePubMed

The changing face of axial spondyloarthritis over the last 25 years

2024Joint bone spinePubMed

Type 1 interferons: A target for immune-mediated inflammatory diseases (IMIDs)

2023Drug discovery todayPubMed

Novel therapeutic strategies for autoimmune and inflammatory rheumatic diseases

2023Rheumatology internationalPubMed

How to optimize recruitment strategies of patients with rheumatic and musculoskeletal diseases for online surveys: experience from an international study

2023Journal of translational autoimmunityPubMed

COVID-19 presentation and outcomes in patients with inflammatory rheumatic and musculoskeletal diseases receiving IL6-receptor antagonists prior to SARS-CoV-2 infection

2025Arthritis & rheumatology (Hoboken, N.J.)PubMed

Maintenance of Remission After Tocilizumab Withdrawal in Patients With Glucocorticoid-Dependent Polymyalgia Rheumatica

2024Autoimmunity reviewsPubMed

The pipeline of immunomodulatory therapies in polymyalgia rheumatica and giant cell arteritis: A systematic review of clinical trials

2024Joint bone spinePubMed

Recommendations of the French Society of Rheumatology for the management in current practice of patients with polymyalgia rheumatica

2024RMD openPubMed

Concordance and agreement between different activity scores in polymyalgia rheumatica

2024CellsPubMed

Subset of DN Memory B Cells Expressing Low Levels of Inhibitory Receptor BTLA Is Enriched in SLE Patients

2024Rheumatology (Oxford, England)PubMed

Prevalence and characteristics of, and knowledge related to, photosensitivity in patients with lupus erythematosus: the international PHOTOLUP study

2023Best practice & research. Clinical rheumatologyPubMed

New and future therapies: Changes in the therapeutic armamentarium for SLE

2023Joint bone spinePubMed

New biologics and targeted therapies in systemic lupus: From new molecular targets to new indications. A systematic review

2024Expert opinion on biological therapyPubMed

IL-17 inhibitors in axial spondyloarthritis. An overview

2023RMD openPubMed

Impact of hyperuricaemia on patients with psoriatic arthritis treated with secukinumab in the FUTURE 2-5 and MAXIMISE studies

2022Rheumatology (Oxford, England)PubMed

New-onset inflammatory bowel diseases among IL-17 inhibitor-treated patients: results from the case-control MISSIL study

2025Arthritis & rheumatology (Hoboken, N.J.)PubMed

Maintenance of Remission After Tocilizumab Withdrawal in Patients With Glucocorticoid-Dependent Polymyalgia Rheumatica

2023The Lancet. RheumatologyPubMed

Abatacept in early polymyalgia rheumatica (ALORS): a proof-of-concept, randomised, placebo-controlled, parallel-group trial

2022JAMAPubMed

Effect of Tocilizumab on Disease Activity in Patients With Active Polymyalgia Rheumatica Receiving Glucocorticoid Therapy: A Randomized Clinical Trial

2026Joint bone spinePubMed

Psoriatic arthritis phase 3 trials: Larger effects, but for whom?

2023RMD openPubMed

Impact of hyperuricaemia on patients with psoriatic arthritis treated with secukinumab in the FUTURE 2-5 and MAXIMISE studies

2023RMD openPubMed

The 2023 pipeline of disease-modifying antirheumatic drugs (DMARDs) in clinical development for spondyloarthritis (including psoriatic arthritis): a systematic review of trials

2025BMC medical educationPubMed

Advancing medical training with augmented reality and haptic feedback simulator: outcomes of a randomized controlled trial on lumbar puncture

2025RMD openPubMed

Efficacy, pharmacokinetics and safety of iscalimab (CFZ533) in patients with proliferative lupus nephritis: a randomised, double-blind, placebo-controlled, phase II study

2025RMD openPubMed

Efficacy, pharmacokinetics and safety of iscalimab (CFZ533) in patients with proliferative lupus nephritis: a randomised, double-blind, placebo-controlled, phase II study

2024RMD openPubMed

Safety and efficacy of colchicine in crystal-induced arthritis flare in 54 patients with severe chronic kidney disease

2026Joint bone spinePubMed

Direct and indirect costs of rheumatoid arthritis and related conditions in France: a 2015-2023 nation-wide population-based study

2024Journal of clinical medicinePubMed

Repurposing the Fibrosis-4 Score in Rheumatoid Arthritis: Data from the ESPOIR Cohort

2025Joint bone spinePubMed

Use of corticosteroid therapy in persistent synovitis following septic arthritis in adults: Report of 12 cases

2022RMD openPubMed

Tolerance and efficacy of targeted therapies prescribed for off-label indications in refractory systemic autoimmune diseases: data of the first 100 patients enrolled in the TATA registry (TArgeted Therapy in Autoimmune Diseases)

2025RMD openPubMed

When generative artificial intelligence answers to Google Trends about spondyloarthritis: what does a French expert panel think about it?

2024Autoimmunity reviewsPubMed

Implementation of regulatory guidance for JAK inhibitors use in patients with immune-mediated inflammatory diseases: An international appropriateness study

2024Autoimmunity reviewsPubMed

The pipeline of immunomodulatory therapies in polymyalgia rheumatica and giant cell arteritis: A systematic review of clinical trials

2022Acta neuropathologica communicationsPubMed

Inclusion body myositis and Sjögren's syndrome: the association works both ways

2026Autophagy reportsPubMed

LC3-associated phagocytosis is impaired in monocyte-derived macrophages from systemic sclerosis patients

2023 · Strasbourg

Identification de nouvelles cibles thérapeutiques au cours du syndrome de Gougerot-Sjögren primitif (SJp)